Archana Sharma-Oates

Dr. Archana Sharma-Oates


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2016 in GigaScience
Verified
Journal Article
Open access
PDF file
RDRobert L Davidson
Robert L Davidson
RWRalf Weber
Ralf Weber
HLHaoyu Liu
Haoyu Liu
ASArchana Sharma-Oates
Archana Sharma-Oates
MVMark Viant
Mark Viant
Background: Metabolomics is increasingly recognized as an invaluable tool in the biological, medical and environmental sciences yet lags behind the methodological maturity of other omics fields. To achieve its full potential, including the integration of multiple omics modalities, the accessibility, standardization and reproducibility of computational metabolomics tools must be improved significantly. Results: Here we present our end-to-end mass spectrometry metabolomics workflow in the widely used platform, Galaxy. Named Galaxy-M, our workflow has been developed for both direct infusion mass spectrometry (DIMS) and liquid chromatography mass spectrometry (LC-MS) metabolomics. The range of tools presented spans from processing of raw data, e.g. peak picking and alignment, through data cleansing, e.g. missing value imputation, to preparation for statistical analysis, e.g. normalization and scaling, and principal components analysis (PCA) with associated statistical evaluation. We demonstrate the ease of using these Galaxy workflows via the analysis of DIMS and LC-MS datasets, and provide PCA scores and associated statistics to help other users to ensure that they can accurately repeat the processing and analysis of these two datasets. Galaxy and data are all provided pre-installed in a virtual machine (VM) that can be downloaded from the GigaDB repository. Additionally, source code, executables and installation instructions are available from GitHub. Conclusions: The Galaxy platform has enabled us to produce an easily accessible and reproducible computational metabolomics workflow. More tools could be added by the community to expand its functionality. We recommend that Galaxy-M workflow files are included within the supplementary information of publications, enabling metabolomics studies to achieve greater reproducibility.

13 October 2022 in BMC Medicine
Verified
Journal Article
Open access
PDF file
ASArchana Sharma-Oates
Archana Sharma-Oates
DZDawit T. Zemedikun
Dawit T. Zemedikun
KKKanta Kumar
Kanta Kumar
JRJohn A. Reynolds
John A. Reynolds
AJAvinash Jain
Avinash Jain
JLJanet M. Lord
Janet M. Lord
Background: The prevalence of some immune-mediated diseases (IMDs) shows distinct differences between populations of different ethnicities. The aim of this study was to determine if the age at diagnosis of common IMDs also differed between different ethnic groups in the UK, suggestive of distinct influences of ethnicity on disease pathogenesis. Methods: This was a population-based retrospective primary care study. Linear regression provided unadjusted and adjusted estimates of age at diagnosis for common IMDs within the following ethnic groups: White, South Asian, African-Caribbean and Mixed-race/Other. Potential disease risk confounders in the association between ethnicity and diagnosis age including sex, smoking, body mass index and social deprivation (Townsend quintiles) were adjusted for. The analysis was replicated using data from UK Biobank (UKB). Results: After adjusting for risk confounders, we observed that individuals from South Asian, African-Caribbean and Mixed-race/Other ethnicities were diagnosed with IMDs at a significantly younger age than their White counterparts for almost all IMDs. The difference in the diagnosis age (ranging from 2 to 30 years earlier) varied for each disease and by ethnicity. For example, rheumatoid arthritis was diagnosed at age 49, 48 and 47 years in individuals of African-Caribbean, South Asian and Mixed-race/Other ethnicities respectively, compared to 56 years in White ethnicities. The earlier diagnosis of most IMDs observed was validated in UKB although with a smaller effect size. Conclusion: Individuals from non-White ethnic groups in the UK had an earlier age at diagnosis for several IMDs than White adults.

1 April 2021 in Cells
Verified
Journal Article
Open access
PDF file
FAFawzeyah A. Alnajjar
Fawzeyah A. Alnajjar
ASArchana Sharma-Oates
Archana Sharma-Oates
SWSusanne Wijesinghe
Susanne Wijesinghe
HFHussein Farah
Hussein Farah
DNDominika Nanus
Dominika Nanus
SJSimon W Jones
Simon W Jones
Metastasis Associated Lung Adenocarcinoma Transcript-1 (MALAT1) is implicated in regulating the inflammatory response and in the pathology of several chronic inflammatory diseases, including osteoarthritis (OA). The purpose of this study was to examine the relationship between OA subchondral bone expression of MALAT1 with parameters of joint health and biomarkers of joint inflammation, and to determine its functional role in human OA osteoblasts. Subchondral bone and blood were collected from hip and knee OA patients (n = 17) and bone only from neck of femur fracture patients (n = 6) undergoing joint replacement surgery. Cytokines were determined by multiplex assays and ELISA, and gene expression by qPCR. MALAT1 loss of function was performed in OA patient osteoblasts using locked nucleic acids. The osteoblast transcriptome was analysed by RNASeq and pathway analysis. Bone expression of MALAT1 positively correlated to serum DKK1 and galectin-1 concentrations, and in OA patient osteoblasts was induced in response to IL-1β stimulation. Osteoblasts depleted of MALAT1 exhibited differential expression (>1.5 fold change) of 155 genes, including PTGS2. Both basal and IL-1β-mediated PGE2 secretion was greater in MALAT1 depleted osteoblasts. The induction of MALAT1 in human OA osteoblasts upon inflammatory challenge and its modulation of PGE2 production suggests that MALAT1 may play a role in regulating inflammation in OA subchondral bone.

17 May 2018 in JCI Insight
Verified
Journal Article
Open access
PDF file
CICharlotte F. Inman
Charlotte F. Inman
SESuzy A. Eldershaw
Suzy A. Eldershaw
JCJoanne E. Croudace
Joanne E. Croudace
NDNathaniel J. Davies
Nathaniel J. Davies
ASArchana Sharma-Oates
Archana Sharma-Oates
PMPaul Moss
Paul Moss
Allogeneic stem cell transplantation (allo-SCT) can cure some patients with hematopoietic malignancy, but this relies on the development of a donor T cell alloreactive immune response. T cell activity in the first 2 weeks after allo-SCT is crucial in determining outcome, despite the clinical effects of the early alloreactive immune response often not appearing until later. However, the effect of the allogeneic environment on T cells is difficult to study at this time point due to the effects of profound lymphopenia. We approached this problem by comparing T cells at week 2 after allograft to T cells from autograft patients. Allograft T cells were present in small numbers but displayed intense proliferation with spontaneous cytokine production. Oligoclonal expansions at week 2 came to represent a substantial fraction of the established T cell pool and were recruited into tissues affected by graft-versus-host disease. Transcriptional analysis uncovered a range of potential targets for immune manipulation, including OX40L, TWEAK, and CD70. These findings reveal that recognition of alloantigen drives naive T cells toward a unique phenotype. Moreover, they demonstrate that early clonal T cell responses are recruited to sites of subsequent tissue damage and provide a range of targets for potential therapeutic immunomodulation.

14 October 2024 in Open Heart
Verified
Journal Article
Open access
PDF file
DWDavid G Wilson
David G Wilson
ASArchana Sharma-Oates
Archana Sharma-Oates
JSJames Sheldon
James Sheldon
DPDaniel F Power
Daniel F Power
JLJanet Lord
Janet Lord
JMJohn M Morgan
John M Morgan
Objective Most patients who have an implantable cardioverter-defibrillator (ICD) implant do not receive life-prolonging therapy from it. Little research has been undertaken to determine which patients benefit the least from ICD therapy. As patients age and accumulate comorbidities, the risk of death increases and the benefit of ICDs diminishes. We sought to evaluate the impact of comorbidity, frailty, functional status on death with no prior appropriate ICD therapy. Methods A prospective, multicentre, observational study involving 12 English hospitals was undertaken. Patients were eligible for inclusion for the study if they were scheduled to have a de novo, upgrade to or replacement of a transvenous or subcutaneous ICD or cardiac resynchronisation therapy device and defibrillator (CRT-D). Baseline characteristics were collected. Participants were asked to complete a frailty assessment (Fried score) and a functional status questionnaire (EuroQol 5-Dimension 5-Level (EQ-5D-5L)). The Charlson Comorbidity Index was calculated. Patients were prospectively followed up for 2.5 years. The primary outcome was death with no prior appropriate therapy. Results In total, 675 patients were enrolled, mean age 65.7 (IQR 65–75) years. A total of 63 patients (9.5%) died during follow-up, 58 without receiving appropriate ICD therapy. Frailty was present in 86/675 (12.7%) and severe comorbidity in 69/675 (10.2%). Multivariate predictors of death with no appropriate therapy were identified and a risk score comprising frailty, comorbidity, increasing age, estimated glomerular filtration rate and EQ-5D-5L was developed. Conclusion Comorbidities, frailty and the EQ-5D-5L score are powerful, independent predictors of death with no prior appropriate therapy in ICD/CRT-D recipients.

17 August 2026 in medRxiv
Verified
Preprint
Open access
PDF file
LNLouise Newman
Louise Newman
NDNiall Dunne
Niall Dunne
VCVinton Cheng
Vinton Cheng
ASArchana Sharma-Oates
Archana Sharma-Oates
Global incidence and outcomes of glioma have been found to vary significantly by region, however research into the disease continues to lack diversity. Here we investigated epigenetic patterns in glioma subtypes from cohorts collected from China and the USA. We retrospectively analysed the Chinese Glioma Genome Atlas (CGGA) and The Cancer Genome Atlas (TCGA) datasets following reclassification of glioma subtypes based on the WHO 2021 central nervous system (CNS) tumour classification. We used DNA methylation and transcriptomics data to identify methylation-driven cancer genes in the CGGA cohort, assessed their prognostic value and compared against the non-Hispanic White cohort in the TCGA database to consider ethnic influence. Furthermore, we used machine learning classification and clustering techniques to identify methylation patterns in glioma subgroups. Here, we showed that DNA methylation profiles of CGGA glioblastomas have a methylation signature more similar to TCGA high-grade astrocytomas: 36.7% of CGGA glioblastomas (n=49) were identified as high-grade astrocytomas using classification modelling. Assessment of survival revealed that CGGA glioblastoma patients had a significantly better survival rate than non-Hispanic White glioblastoma patients (p = 0.037). Four key methylation-driven genes were identified in the CGGA glioblastoma samples: GLDN, PRKDC, S100A1 and NCAPH. Hypermethylation of GLDN significantly suppressed gene expression in all glioma subtypes in only the East Asian cohort; a gene that has not been previously described as a driver in gliomas. Together these data suggest alternative epigenetic mechanisms occurring in glioma subtypes of different ethnic populations, which is important for our understanding of glioma and strategies for personalized treatment.